Article · 24 Jun 2026
Case reportPublished 2017
Left Ventricular Perforation in A Patient with Lung Cancer Treated with Bevacizumab
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
In addition to traditional chemotherapeutic regimens molecular targeted agents emerged as new therapeutic options for the treatment of non-small-cell lung cancer (NSCLC). These targeted therapies do not have the same systemic adverse effects usually observed with traditional cytotoxic drugs, but feature a specific spectrum of characteristic adverse effects. The humanized monoclonal antibody against the VEGF-A ligand Bevacizumab inhibits angiogenesis. The characteristic toxicities of Bevacizumab include hemorrhage, wound healing complications, gastrointestinal perforation, arterial thromboembolism, and infusion-related hypersensitivity reactions. We present a unique case of a left ventricular wall perforation after myocardial infarction associated with the administration of Bevacizumab in NSCLC. Cardiac MRI follow-up showed regression of the ventricular perforation.
Subjects
CardiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Interventional Cardiology Journal.
Article · 24 Jun 2026
Valve Calcification: Causes, Clinical Manifestations, Diagnosis, and Current Management
Article · 24 Jun 2026
Aortic Regurgitation: Causes, Clinical Features, Diagnosis, and Treatment Options
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalInterventional Cardiology Journal
- SubjectCardiology
- BylineArticles whose byline prints “Mirjam Keßler”
- BylineArticles whose byline prints “Wolfgang Rottbauer”
- BylineArticles whose byline prints “Jochen Wöhrle”